Gamma knife radiosurgery for the treatment of brain metastases

Stereotact Funct Neurosurg. 2000;74(1):37-51. doi: 10.1159/000056462.

Abstract

One hundred and ninety-three patients with brain metastases from various primary sites received Gamma Knife radiosurgery (GKR) from July 1992 to August 1997 and were reviewed to evaluate their clinical outcome. Survival follow-up was available on 173 patients. Whole-brain radiation therapy was also administered to 148 of these patients. The median survival was 13.1 months from initial detection of brain metastases, and 7.5 months from GKR. Univariate and multivariate analyses were performed to determine prognostic factors that influenced survival following GKR. Enhanced survival is observed in patients with radiosensitive tumor types, supratentorial tumor, history of brain tumor resection, controlled primary site, and absent extracranial metastases. Local lesion control was obtained in 82% of the patients according to their last follow-up MRI scan. GKR is an effective means of treating patients with brain metastases.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Neoplasms / mortality
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / surgery
  • Carcinoma / mortality
  • Carcinoma / radiotherapy
  • Carcinoma / secondary*
  • Carcinoma / surgery
  • Combined Modality Therapy
  • Cranial Irradiation
  • Female
  • Follow-Up Studies
  • Humans
  • Life Tables
  • Magnetic Resonance Imaging
  • Male
  • Melanoma / mortality
  • Melanoma / radiotherapy
  • Melanoma / secondary*
  • Melanoma / surgery
  • Middle Aged
  • Palliative Care
  • Prognosis
  • Proportional Hazards Models
  • Radiation Tolerance
  • Radiosurgery* / instrumentation
  • Retrospective Studies
  • Supratentorial Neoplasms / mortality
  • Supratentorial Neoplasms / radiotherapy
  • Supratentorial Neoplasms / secondary
  • Supratentorial Neoplasms / surgery
  • Survival Analysis
  • Treatment Outcome